HealthSummit Says FDA Rejected Ivonescimab Application Over Survival EvidenceBy Naomi CalderNov 15, 2026, 6:50 PM UTC
HealthChina Phase II Study Reports 50.7% Pathological Complete Response With IvonescimabBy Naomi CalderNov 6, 2026, 2:39 PM UTC
HealthAkeso, Inc. Reports Longer Survival With Ivonescimab in Biliary Tract Cancer TrialBy Naomi CalderOct 25, 2026, 3:49 PM UTC
